BioAlliance has generated a consolidated turnover of 604.
000 euros in the first quarter, up to the tune of 560,000 euros in revenues related to business partnerships on Loramyc, its drug against oropharyngeal candidiasis in immunocompromised patients.
The biopharmaceutical company said that the income is an amount comparable to sales recorded on its flagship product in the first quarter of 2010, although it is more direct sales but revenue from the partnership.
"(...) BioAlliance continues its strategy of partnership Loramyc, notably through the recent agreement signed with Sosei for Japan, "said Nicolas Fellmann, Chief Financial Officer.
In total, more than 8.5 million of revenue which are programmed over the year, thanks to partnership agreements already signed.
The consolidated cash BioAlliance was 16.2 million euros as of March 31.
000 euros in the first quarter, up to the tune of 560,000 euros in revenues related to business partnerships on Loramyc, its drug against oropharyngeal candidiasis in immunocompromised patients.
The biopharmaceutical company said that the income is an amount comparable to sales recorded on its flagship product in the first quarter of 2010, although it is more direct sales but revenue from the partnership.
"(...) BioAlliance continues its strategy of partnership Loramyc, notably through the recent agreement signed with Sosei for Japan, "said Nicolas Fellmann, Chief Financial Officer.
In total, more than 8.5 million of revenue which are programmed over the year, thanks to partnership agreements already signed.
The consolidated cash BioAlliance was 16.2 million euros as of March 31.